Endo Obtains Preliminary Injunction Against QuVa Pharma, Inc. Preventing Marketing and Release of Vasopressin Product

DUBLIN, March 1, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC (Par), have obtained a preliminary injunction preventing QuVa Pharma, Inc. (QuVa) from marketing and releasing its planned vasopressin product that would compete with Par's Vasostrict®, the first and only vasopressin injection, USP, product approved by the U.S. Food and Drug Administration. The preliminary injunction, issued today by the Hon. Brian R. Martinotti, U.S. District Judge, is effective through the conclusion of a trial, which has not yet been scheduled.

In August 2017, Par filed a complaint against QuVa and several individual defendants in the U.S. District Court for the District of New Jersey (Case No. 17-6115) alleging, among other claims, the misappropriation of Par's trade secrets by the defendants in connection with QuVa's development of a bulk compounded vasopressin product.

"Endo embraces principles of fair competition. In fact, our competitors keep us striving to improve our products and services. That said, fair competition does not extend to the misappropriation of our valuable information. We initiated this litigation because we have a responsibility to protect our Company and prevent other parties from obtaining an improper and unfair advantage in the marketplace," said Matthew J. Maletta, Executive Vice President and Chief Legal Officer of Endo. "We look forward to pursuing this case through trial where we will seek permanent injunctive relief, together with the recovery of all appropriate damages from QuVa, the individual defendants and potentially other parties not yet named in the litigation."